CRISPR Therapeutics (CRSP) Stock Price
CRISPR Therapeutics Price
CRISPR Therapeutics (CRSP) Stock | ISIN CH0334081137 | WKN A2AT0Z. The current CRISPR Therapeutics stock price is 50.22 USD (2026). Revenue is 59.78 M USD. Net income is -388.11 M USD. The P/E ratio is -11.64. Market capitalization is 4.79 B USD. CRISPR Therapeutics operates in the Health sector.
CRISPR Therapeutics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of CRISPR Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how CRISPR Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing CRISPR Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | CRISPR Therapeutics Price |
|---|
CRISPR Therapeutics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
CRISPR Therapeutics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales CRISPR Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue CRISPR Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare CRISPR Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares CRISPR Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against CRISPR Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
CRISPR Therapeutics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
CRISPR Therapeutics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
CRISPR Therapeutics business model & stock analysis
CRISPR Therapeutics SWOT Analysis
Strengths
1. Strong Intellectual Property: CRISPR Therapeutics AG possesses a robust portfolio of patents related to CRISPR gene-editing technology, providing them with a competitive advantage in the market.
2. Cutting-Edge Technology: The company specializes in developing innovative gene therapies utilizing CRISPR-Cas9, a revolutionary genome editing technique with immense potential for treating genetic diseases.
3. Strategic Partnerships: CRISPR Therapeutics AG has established collaborations with leading pharmaceutical companies, which strengthens their research capabilities, expands their reach, and facilitates licensing opportunities.
Weaknesses
1. Limited Clinical Pipeline: Although CRISPR Therapeutics AG has several promising programs in preclinical and early clinical stages, their current pipeline of potential therapies is relatively small compared to some competitors.
2. Regulatory Challenges: As with any novel therapeutic approach, CRISPR gene editing faces regulatory hurdles and ethical concerns, which may delay approval processes and affect market adoption.
Opportunities
1. Unmet Medical Needs: The increasing prevalence of genetic disorders combined with limited treatment options presents a significant opportunity for CRISPR Therapeutics AG to address unmet medical needs and create breakthrough therapies.
2. Expansion into New Indications: CRISPR gene editing has the potential to be applied beyond genetic diseases, such as cancer immunotherapies or agricultural advancements. CRISPR Therapeutics AG can explore these new indications to diversify their product portfolio.
Threats
1. Competition: CRISPR Therapeutics AG operates in a highly competitive landscape with other biotechnology companies also exploring gene-editing technologies. Increased competition may affect market share and limit pricing power.
2. Intellectual Property Disputes: There is ongoing litigation and disputes surrounding the intellectual property rights related to CRISPR-Cas9 technology, which may impact the exclusivity and commercialization opportunities for CRISPR Therapeutics AG.
CRISPR Therapeutics Segments
CRISPR Therapeutics Revenue by Segment
3 Years
5 Years
Max
Details
CRISPR Therapeutics Eulerpool Fair Value
CRISPR Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio
CRISPR Therapeutics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
CRISPR Therapeutics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
CRISPR Therapeutics Earnings Estimates
CRISPR Therapeutics Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/11/2026 | -1.25USD | 2.75 MUSD | 2026 Q1 |
| 5/4/2026 | -1.25USD | 2.75 MUSD | 2026 Q1 |
| 2/17/2026 | -1.17USD | 4.33 MUSD | 2025 Q4 |
| 2/9/2026 | -1.19USD | 4.33 MUSD | 2025 Q4 |
| 11/1/2022 | -2.34USD | 1.64 MUSD | 2022 Q3 |
| 8/8/2022 | -2.27USD | 2.09 MUSD | 2022 Q2 |
| 5/9/2022 | -1.98USD | 2.81 MUSD | 2022 Q1 |
| 2/15/2022 | -1.8USD | 2.31 MUSD | 2021 Q4 |
| 11/3/2021 | -1.79USD | 1.14 MUSD | 2021 Q3 |
| 7/29/2021 | 3.59USD | 427.24 MUSD | 2021 Q2 |
EESG©
Eulerpool ESG Scorecard© for the CRISPR Therapeutics stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
CRISPR Therapeutics shareholder structure
| % | Name |
|---|---|
10.68477% | |
5.86962% | |
5.68625% | |
3.86467% | |
3.4319% | |
3.03323% | |
2.90087% | |
2.71515% | |
2.53334% | |
2.39144% |
CRISPR Therapeutics Executives and Management Board
Dr. Samarth Kulkarni
(46)Chairman of the Board, Chief Executive Officer · since 2017
Dr. Naimish Patel
(53)Chief Medical Officer
Mr. James Kasinger
(53)General Counsel, Secretary
Dr. Raju Prasad
(41)Chief Financial Officer
Mr. Christian Rommel
(58)Independent Director
CRISPR Therapeutics Supply Chain
Frequently asked questions about CRISPR Therapeutics
The business model of CRISPR Therapeutics AG is focused on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 gene-editing platform. The company aims to address a wide range of severe diseases by leveraging the potential of CRISPR technology to correct genetic defects. CRISPR Therapeutics AG collaborates with various partners to advance its pipeline of therapeutic candidates, spanning areas like hematology, oncology, ophthalmology, and regenerative medicine. Their goal is to bring novel and curative treatments to patients with unmet medical needs. CRISPR Therapeutics AG prioritizes innovation, strategic alliances, and continuous research to drive the advancement of gene-based therapies.
CRISPR Therapeutics stock
CRISPR Therapeutics Peer Group
CRISPR Therapeutics Ticker
CRISPR Therapeutics FIGI
All fundamentals and in-depth analysis of CRISPR Therapeutics
Our stock analysis for CRISPR Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CRISPR Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.